{
  "id": 13263299,
  "title": "China wants 5 innovative drugs with US$1 billion returns by 2030. Which might they be?",
  "url": "https://urgent.news/2026/10/10/china-wants-5-innovative-drugs-with-us-1-billion-returns-by-2030",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-10T00:00:20.000Z",
  "source": {
    "name": "SCMP Business",
    "slug": "scmp-business",
    "url": "https://www.scmp.com/business/china-business/article/3370340/china-wants-5-innovative-drugs-us1-billion-returns-2030-which-might-they-be"
  },
  "original_language": "en",
  "account": "China aims to achieve groundbreaking achievements in drug development by 2030, targeting five innovative therapies with annual sales of over US$1 billion each. Some leading contenders in this endeavor include BeOne's zanubrutinib, which has already surpassed US$3.9 billion in global revenue as a treatment for blood cancers. Legend Biotech's Carvykti, developed in collaboration with Johnson & Johnson, has also met the sales target, amounting to US$1.9 billion in 2025. Akeso's ivonescimab, which outperformed Merck's Keytruda in lung cancer trials, has the potential to generate US$8.5 billion in sales by 2032, as projected by Evaluate. Tislelizumab, BeOne's second-highest-grossing drug, and Kelun-Biotech's sacituzumab tirumotecan are also considered strong candidates for reaching the US$1 billion sales milestone by the end of the decade.",
  "summary": "The increasing global appeal of Chinese firms’ novel therapies has propelled the country’s rise as a biomedical powerhouse, but China has yet to produce a drug to rival all-time best-selling Western blockbusters in sales. Beijing has set ambitious new five-year targets to boost its global presence, including at least five products with annual global sales surpassing US$1 billion by 2030. The goal…",
  "key_points": [
    "China targets five innovative drugs with US$1 billion annual sales by 2030.",
    "BeOne's zanubrutinib generated over US$3.9 billion in global revenue.",
    "Carvykti by Legend Biotech and ivonescimab by Akeso are also strong candidates."
  ],
  "editors_take": "China's push for five innovative therapies with over $1 billion in annual sales by 2030 cements its ambition to become a major player in global drug development.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}